Are there any specific research areas that are excluded from EMRISTA Research Awards?

Are there any specific research areas that are excluded from EMRISTA Research Awards?

The following topics fall outside of the scope of the EMRISTA Research Program:
 

  • Patient populations where the risk of NOACs use is greater than the benefit
  • A use that is contraindicated in the apixaban prescribing information or outside of product label
  • Pregnant and lactating women • Any head-to-head clinical trial comparison of apixaban versus another novel oral anticoagulant [NOAC])
  • Repeat/duplication of research, (e.g. ablation, reversal or “acute” cardioversion)
  • Repeat of any Phase 3 trials
  • Any pharmacokinetic/pharmacodynamic properties described in the USPI e.g. crushed tablets, hemodialysis
  • Reducing the recurrence of acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)
  • Post coronary artery bypass graft (CABG), prosthetic (mechanical and bioprosthetic heart valves or devices)
  • Patients with any atherothrombotic or hemorrhagic stroke, or any stroke within 7 days
  • Venous thromboembolism prophylaxis (VTEp) in patients with stroke and hemiparesis
  • Evaluation of the safety of apixaban in patients with end-stage renal disease on hemodialysis
  • Efficacy of apixaban in secondary prevention of TIA/CVA. top

 

FAQ Category:

FAQ Tag: 
excluded